2 Stocks I'm Buying In The Next 2 Weeks
1 extracted signal · 1 resolved · 0 still active
The Patient InvestorIndependent analyst profile- Source published
- 18 Jul 2026, 17:46 UTC
- Recorded by Tahlil Plus
- 18 Jul 2026, 19:03 UTC
AI-generated source summary
The analysis discusses two primary investment opportunities: OUST and AIA. OUST, currently trading around $37.04, is analyzed as a stock that has experienced a significant decline, down approximately 40% from its all-time high. Despite recent losses, its year-to-date performance is still up by 58.49%. The company's financial health is noted as improving, with a projected path to profitability by late 2027, supported by $450 million in cash and no debt. The market trend for OUST is observed as bearish, with a target price of $20.00 and a failure bound at $35.00. The analysis also highlights the company's strong revenue growth guidance of 30-50% annually for the next few years, with gross margins anticipated between 35-40%. Ouster's market position as a leader in LiDAR technology is emphasized, particularly its competitive advantage in the automotive and industrial sectors due to its US-based manufacturing and advanced technology, which could allow it to command higher prices and secure significant market share. However, the company has posted losses for several quarters. The second opportunity discussed is the iShares Asia 50 ETF (AIA), trading around $130.08, which has seen a monthly decline of 9.51%. The ETF is trading at a forward P/E ratio of approximately 12.56, with projected long-term earnings growth of 15.26%. While currently showing a bearish trend, the analysis suggests a potential shift to bullish, with a target of $135.00 and a failure bound at $125.00. The ETF is noted for its diversified holdings across 50 of the largest Asian equities, offering exposure to sectors like technology and automotive, with a relatively low expense ratio of 0.50%. The analysis indicates that a significant portion of the ETF's holdings are from Chinese companies, which may face regulatory challenges, but Ouster's US-based positioning is seen as a strategic advantage.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.